中枢神経系（CNS）治療薬市場：疾患タイプ別：2024年～2033年の世界機会分析と産業予測

中枢神経系（CNS）治療薬市場は、2023年には1,141億4,558万米ドルと評価され、2033年には1,990億9,830万米ドルに達すると推定され、2024年から2033年までのCAGRは5.7%です。

中枢神経系（CNS）は、神経と細胞の複雑なネットワークであり、身体の活動の調整と調節に重要な役割を果たしています。中枢神経系は脳と脊髄で構成され、神経系全体の主要な制御センターとしての役割を果たしています。中枢神経系の治療薬は、症状を緩和し、認知機能を改善し、疾患の進行を遅らせることを目的としています。中枢神経系の治療には、主に中枢神経系内の障害や不均衡に対処するための薬剤の使用が含まれます。アルツハイマー病やパーキンソン病などの神経変性疾患から、気分障害、不安障害、精神病性障害などの精神疾患まで、さまざまな神経疾患や精神疾患を対象としています。

中枢神経系（CNS）治療薬市場は、CNS疾患の有病率の急増や、研究やイノベーションを支援する研究助成金などの政府主導により、大きな成長が見込まれています。中枢神経系（CNS）疾患の有病率の増加は、中枢神経系（CNS）治療薬市場の主要な促進要因として浮上しています。この背景には、ストレスの多いライフスタイル、メンタルヘルスに対する怠慢、老年人口の増加があります。特に高齢化社会では、アルツハイマー病やパーキンソン病などの神経変性疾患が急増しています。例えば、米国疾病予防管理センターによると、65歳以上のアメリカ人の約670万人がアルツハイマー病にかかっていると推定されています。

さらに、高いストレスレベルと座りっぱなしの習慣が特徴的な、現代的でペースの速いライフスタイルは、不安やうつ病のような精神疾患のリスクの高まりと関連しています。例えば、国立医学図書館によると、2021年には米国成人の5人に1人以上が精神疾患を抱えていると推定されています。製薬会社は、さまざまな中枢神経系疾患をターゲットとした新薬や治療法の発見・開発にますます力を注いでいます。神経科学におけるブレークスルーと、これらの疾患の根本的なメカニズムの深い理解により、より効果的で的を絞った治療法への道が開かれました。患者やヘルスケアプロバイダーが症状を緩和するだけでなく、中枢神経系疾患の根本原因に対処する高度な介入を求めるようになり、中枢神経系治療薬の需要は急増すると予想されます。このように、中枢神経系（CNS）疾患の有病率の増加は、中枢神経系（CNS）治療薬市場の成長に大きく寄与すると予想されます。

さらに、中枢神経系障害の治療における研究や技術革新を支援するための調査助成金など、政府の有利なイニシアチブが市場の成長を促進すると予想されます。世界各国の政府は、神経変性疾患、精神疾患、神経疾患などの疾患への対処の必要性を認識しており、これらの疾患は世界のヘルスケアシステムに大きな負担となっています。研究を推進する注目すべきイニシアチブのひとつに、中枢神経系の理解を深め、新規の治療介入を開発することに特化した研究助成金の提供があります。研究助成金は科学的探求の触媒として機能し、研究者、学界、製薬企業間の協力を促進します。例えば、米国パーキンソン病協会では、研究科学者に最高7万5,000米ドルの研究助成金を授与しています。米国パーキンソン病協会研究助成金は、パーキンソン病の病態生理学、病因、治療に関する新たな知見を得ることを目的とした研究を支援することを目的としています。

助成金の提案では、基礎科学からリハビリテーションに焦点を当てたプロジェクトまで、あらゆる研究課題に取り組むことができます。American Parkinson Disease Associationは、パーキンソン病研究分野への新しい研究者の参入を促進するとともに、この分野における調査に値する重要な新しいアイデアを支援することを目指しています。政府機関は助成金を提供することで、革新的な治療法や療法の開発を促進する上で極めて重要な役割を果たしています。このように、研究助成金のような政府の有利なイニシアチブは、市場の成長を促進すると予想されます。

しかし、中枢神経系（CNS）治療薬のコストが高いことが、市場の成長を抑制する主な懸念事項として浮上しています。神経疾患の複雑な性質は、しばしば高度で専門的な治療介入を必要とし、研究開発費の高騰につながっています。さらに、保健当局が課す厳しい規制要件は、中枢神経系疾患の治療薬を市場に送り出すまでに長期間を要し、リソースを集中させる一因となっています。こうした多額のコストは、患者やヘルスケアシステムからなるエンドユーザーに転嫁されるため、中枢神経系治療薬へのアクセスや購入のしやすさが制限されることになります。したがって、中枢神経系（CNS）治療薬のコストが高いことが、市場の成長を抑制する可能性があります。

中枢神経系（CNS）治療薬市場は、疾患タイプと地域によって区分されます。疾患タイプ別では、神経血管疾患、中枢神経系外傷、メンタルヘルス、神経変性疾患、感染症、がん、その他に分けられます。メンタルヘルス分野はさらに、メンタルヘルス不安障害、てんかん、気分障害、精神病性障害、その他に区分されます。

また、神経変性疾患はさらにアルツハイマー病、パーキンソン病、多発性硬化症、ハンチントン病、筋萎縮性側索硬化症、その他に分類されます。地域別では、市場は北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州地域）、アジア太平洋地域（中国、日本、オーストラリア、インド、韓国、その他アジア太平洋地域）、アジア太平洋地域（ブラジル、日本、アラビア、オーストラリア、インド、韓国、その他アジア太平洋地域）で分析されます。

利害関係者にとっての主なメリット

• 当レポートは、2023年から2033年までの中枢神経系（cns）治療薬市場分析の市場セグメント、現在の動向、推定・動向、力学の定量分析を提供し、有力な中枢神経系（cns）治療薬市場機会を特定します。
• 市場促進要因、市場抑制要因、市場機会に関連する情報とともに市場調査を提供します。
• ポーターのファイブフォース分析では、利害関係者が利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるよう、バイヤーとサプライヤーの潜在力を強調します。
• 中枢神経系（CNS）治療薬市場のセグメンテーションの詳細な分析は、市場機会を決定するのに役立ちます。
• 各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
• 市場プレイヤーのポジショニングはベンチマークを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
• 地域別および世界の中枢神経系（cns）治療薬市場動向、主要企業、市場セグメント、応用分野、市場成長戦略などの分析を含みます。

本レポートで可能なカスタマイズ（追加費用とスケジュールが必要です。）

• 顧客の関心に応じた企業プロファイルの追加
• 企業プロファイルの拡張リスト
• 過去の市場データ

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

• 市場の定義と範囲
• 主な調査結果
  • 影響要因
  • 主な投資機会
• ポーターのファイブフォース分析
• 市場力学
  • 促進要因
    • 神経疾患の有病率の上昇
    • 中枢神経系疾患に対する認識と診断の高まり
    • 主要企業による研究開発の急増
  • 抑制要因
    • 中枢神経系（CNS）治療薬の高コスト
  • 機会
    • ドラッグデリバリーの技術的進歩

第4章 中枢神経系（CNS）治療薬市場：疾患タイプ別

• 概要
• 神経血管疾患
• 中枢神経系外傷
• メンタルヘルス
  • メンタルヘルス疾患タイプ別中枢神経系（CNS）治療薬市場
• 神経変性疾患
  • 神経変性疾患の中枢神経系（CNS）治療薬市場：疾患タイプ別
• 感染症
• 中枢神経系がん
• その他

第5章 中枢神経系（CNS）治療薬市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • その他
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • その他
• ラテンアメリカ・中東・アフリカ
  • ブラジル
  • サウジアラビア
  • 南アフリカ
  • その他

第6章 競争情勢

• イントロダクション
• 主要成功戦略
• 主要10社の製品マッピング
• 競合ダッシュボード
• 競合ヒートマップ
• 主要企業のポジショニング、2023年

第7章 企業プロファイル

• Johnson and Johnson
• Eli Lilly and Company.
• Merck & Co Inc
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• F. Hoffmann-La Roche AG
• Takeda Pharmaceutical Company Ltd.
• Viatris Inc.
• UCB Pharma
• Biogen

LIST OF TABLES

• TABLE 01. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 02. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR NEUROVASCULAR DISEASES, BY REGION, 2023-2033 ($MILLION)
• TABLE 03. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR CNS TRAUMA, BY REGION, 2023-2033 ($MILLION)
• TABLE 04. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR MENTAL HEALTH, BY REGION, 2023-2033 ($MILLION)
• TABLE 05. GLOBAL MENTAL HEALTH CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 06. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2023-2033 ($MILLION)
• TABLE 07. GLOBAL NEURODEGENERATIVE DISEASES CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 08. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2033 ($MILLION)
• TABLE 09. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR CNS CANCER, BY REGION, 2023-2033 ($MILLION)
• TABLE 10. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2023-2033 ($MILLION)
• TABLE 11. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY REGION, 2023-2033 ($MILLION)
• TABLE 12. NORTH AMERICA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 13. NORTH AMERICA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
• TABLE 14. U.S. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 15. CANADA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 16. MEXICO CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 17. EUROPE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 18. EUROPE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
• TABLE 19. GERMANY CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 20. FRANCE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 21. UK CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 22. ITALY CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 23. SPAIN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 24. REST OF EUROPE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 25. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 26. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
• TABLE 27. JAPAN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 28. CHINA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 29. INDIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 30. AUSTRALIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 31. SOUTH KOREA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 32. REST OF ASIA-PACIFIC CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 33. LAMEA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 34. LAMEA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
• TABLE 35. BRAZIL CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 36. SAUDI ARABIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 37. SOUTH AFRICA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 38. REST OF LAMEA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
• TABLE 39. JOHNSON AND JOHNSON: KEY EXECUTIVES
• TABLE 40. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
• TABLE 41. JOHNSON AND JOHNSON: PRODUCT SEGMENTS
• TABLE 42. JOHNSON AND JOHNSON: SERVICE SEGMENTS
• TABLE 43. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
• TABLE 44. ELI LILLY AND COMPANY.: KEY EXECUTIVES
• TABLE 45. ELI LILLY AND COMPANY.: COMPANY SNAPSHOT
• TABLE 46. ELI LILLY AND COMPANY.: PRODUCT SEGMENTS
• TABLE 47. ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO
• TABLE 48. ELI LILLY AND COMPANY.: KEY STRATERGIES
• TABLE 49. MERCK & CO INC: KEY EXECUTIVES
• TABLE 50. MERCK & CO INC: COMPANY SNAPSHOT
• TABLE 51. MERCK & CO INC: PRODUCT SEGMENTS
• TABLE 52. MERCK & CO INC: PRODUCT PORTFOLIO
• TABLE 53. NOVARTIS AG: KEY EXECUTIVES
• TABLE 54. NOVARTIS AG: COMPANY SNAPSHOT
• TABLE 55. NOVARTIS AG: PRODUCT SEGMENTS
• TABLE 56. NOVARTIS AG: PRODUCT PORTFOLIO
• TABLE 57. NOVARTIS AG: KEY STRATERGIES
• TABLE 58. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
• TABLE 59. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
• TABLE 60. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
• TABLE 61. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
• TABLE 62. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
• TABLE 63. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
• TABLE 64. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
• TABLE 65. F. HOFFMANN-LA ROCHE AG: PRODUCT SEGMENTS
• TABLE 66. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
• TABLE 67. TAKEDA PHARMACEUTICAL COMPANY LTD.: KEY EXECUTIVES
• TABLE 68. TAKEDA PHARMACEUTICAL COMPANY LTD.: COMPANY SNAPSHOT
• TABLE 69. TAKEDA PHARMACEUTICAL COMPANY LTD.: PRODUCT SEGMENTS
• TABLE 70. TAKEDA PHARMACEUTICAL COMPANY LTD.: PRODUCT PORTFOLIO
• TABLE 71. VIATRIS INC.: KEY EXECUTIVES
• TABLE 72. VIATRIS INC.: COMPANY SNAPSHOT
• TABLE 73. VIATRIS INC.: PRODUCT SEGMENTS
• TABLE 74. VIATRIS INC.: PRODUCT PORTFOLIO
• TABLE 75. UCB PHARMA: KEY EXECUTIVES
• TABLE 76. UCB PHARMA: COMPANY SNAPSHOT
• TABLE 77. UCB PHARMA: PRODUCT SEGMENTS
• TABLE 78. UCB PHARMA: PRODUCT PORTFOLIO
• TABLE 79. BIOGEN: KEY EXECUTIVES
• TABLE 80. BIOGEN: COMPANY SNAPSHOT
• TABLE 81. BIOGEN: PRODUCT SEGMENTS
• TABLE 82. BIOGEN: PRODUCT PORTFOLIO
• TABLE 83. BIOGEN: KEY STRATERGIES

LIST OF FIGURES

• FIGURE 01. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033
• FIGURE 02. SEGMENTATION OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET,2023-2033
• FIGURE 03. TOP IMPACTING FACTORS IN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET (2023 TO 2033)
• FIGURE 04. TOP INVESTMENT POCKETS IN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET (2024-2033)
• FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
• FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
• FIGURE 07. LOW THREAT OF SUBSTITUTES
• FIGURE 08. HIGH INTENSITY OF RIVALRY
• FIGURE 09. LOW BARGAINING POWER OF BUYERS
• FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
• FIGURE 11. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023 AND 2033(%)
• FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR NEUROVASCULAR DISEASES, BY COUNTRY 2023 AND 2033(%)
• FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR CNS TRAUMA, BY COUNTRY 2023 AND 2033(%)
• FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR MENTAL HEALTH, BY COUNTRY 2023 AND 2033(%)
• FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY 2023 AND 2033(%)
• FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY 2023 AND 2033(%)
• FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR CNS CANCER, BY COUNTRY 2023 AND 2033(%)
• FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY 2023 AND 2033(%)
• FIGURE 19. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET BY REGION, 2023 AND 2033(%)
• FIGURE 20. U.S. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
• FIGURE 21. CANADA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
• FIGURE 22. MEXICO CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
• FIGURE 23. GERMANY CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
• FIGURE 24. FRANCE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
• FIGURE 25. UK CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
• FIGURE 26. ITALY CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
• FIGURE 27. SPAIN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
• FIGURE 28. REST OF EUROPE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
• FIGURE 29. JAPAN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
• FIGURE 30. CHINA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
• FIGURE 31. INDIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
• FIGURE 32. AUSTRALIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
• FIGURE 33. SOUTH KOREA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
• FIGURE 34. REST OF ASIA-PACIFIC CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
• FIGURE 35. BRAZIL CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
• FIGURE 36. SAUDI ARABIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
• FIGURE 37. SOUTH AFRICA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
• FIGURE 38. REST OF LAMEA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
• FIGURE 39. TOP WINNING STRATEGIES, BY YEAR (2020-2024)
• FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2024)
• FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY (2020-2024)
• FIGURE 42. PRODUCT MAPPING OF TOP 10 PLAYERS
• FIGURE 43. COMPETITIVE DASHBOARD
• FIGURE 44. COMPETITIVE HEATMAP: CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET
• FIGURE 45. TOP PLAYER POSITIONING, 2023
• FIGURE 46. JOHNSON AND JOHNSON: NET REVENUE, 2020-2022 ($MILLION)
• FIGURE 47. JOHNSON AND JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 48. JOHNSON AND JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 49. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
• FIGURE 50. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 51. MERCK & CO INC: NET SALES, 2020-2022 ($MILLION)
• FIGURE 52. MERCK & CO INC: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 53. MERCK & CO INC: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 54. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
• FIGURE 55. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 56. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 57. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
• FIGURE 58. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 59. F. HOFFMANN-LA ROCHE AG: NET REVENUE, 2020-2022 ($MILLION)
• FIGURE 60. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 61. TAKEDA PHARMACEUTICAL COMPANY LTD.: NET REVENUE, 2020-2022 ($MILLION)
• FIGURE 62. TAKEDA PHARMACEUTICAL COMPANY LTD.: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 63. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
• FIGURE 64. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 65. UCB PHARMA: NET REVENUE, 2020-2022 ($MILLION)
• FIGURE 66. UCB PHARMA: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 67. BIOGEN: NET REVENUE, 2020-2022 ($MILLION)
• FIGURE 68. BIOGEN: REVENUE SHARE BY REGION, 2022 (%)

The Central Nervous System (CNS) Therapeutics Market was valued for $114,145.58 million in 2023 and is estimated to reach $199,098.30 million by 2033, exhibiting a CAGR of 5.7% from 2024 to 2033. The central nervous system (CNS) is a complex network of nerves and cells that play a crucial role in coordinating and regulating the body's activities. It comprises the brain and spinal cord, serving as the primary control center for the entire nervous system. Central nervous system therapeutics aim to alleviate symptoms, improve cognitive function, and slow down disease progression. Central nervous system therapeutics primarily involve the use of drugs to address disorders and imbalances within the central nervous system. The medications target various neurological and psychiatric conditions, ranging from neurodegenerative diseases like Alzheimer's and Parkinson's to mental health disorders such as mood disorders, anxiety, and psychotic disorders.

The central nervous system (CNS) therapeutics market is expected to register significant growth, owing to surge in prevalence of CNS disorders, and favorable government initiative such as research grants to support research and innovation. The rise in prevalence of CNS disorders has emerged as a major driver for the central nervous system (CNS) therapeutics market. This can be attributed to the stressful lifestyle, negligence towards mental health, and rise in geriatric population. The aging population, in particular, has witnessed a surge in neurodegenerative conditions such as Alzheimer's and Parkinson's diseases. For instance, according to Center for Disease Control and Prevention, it was estimated that around 6.7 million Americans aged 65 years or older had Alzheimer's disease.

Additionally, the modern, fast-paced lifestyle, marked by high stress levels and sedentary habits, has been associated with a heightened risk of mental health disorders like anxiety and depression. For instance, according to National Library of Medicine, in 2021, it was estimated that that more than one in five U.S. adults live with a mental illness. Pharmaceutical companies are increasingly focusing on the discovery and development of novel drugs and therapies targeting various CNS conditions. Breakthroughs in neuroscience and a deeper understanding of the underlying mechanisms of these disorders have paved the way for more effective and targeted treatment options. The demand for CNS therapeutics is expected to surge as patients and healthcare providers seek advanced interventions that not only alleviate symptoms but also address the root causes of the CNS disorders. Thus, the rise in prevalence of CNS disorders is expected to contribute significantly to the growth of the central nervous system (CNS) therapeutics market.

In addition, favorable government initiatives such as research grants to support research and innovation in treating central nervous system disorders are expected to drive the growth of the market. Governments around the world are recognizing the critical need to address conditions such as neurodegenerative diseases, psychiatric disorders, and neurological disorders, which collectively pose a substantial burden on global healthcare systems. One notable initiative driving the research is the provision of research grants specifically dedicated to advancing our understanding of the central nervous system and developing novel therapeutic interventions. The research grants serve as a catalyst for scientific exploration, fostering collaboration between researchers, academia, and pharmaceutical companies. For instance, American Parkinson Disease Association, awards research grant of maximum of $75,000 to research scientists. American Parkinson Disease Association Research Grants are intended to support research aimed at developing new insights into the pathophysiology, etiology and treatment of Parkinson's disease.

Grant proposals can address research questions anywhere along the pipeline from basic science to rehabilitation-focused projects. American Parkinson Disease Association seeks to promote the entry of new investigators into the field of Parkinson research, as well as to support important new ideas in the field worthy of investigation. By providing grants governments agencies are playing a pivotal role in accelerating the development of innovative treatments and therapies. Thus, favorable government initiatives such as research grants are expected to drive the growth of the market.

However, the high cost of the central nervous system (CNS) therapeutic drug has emerged as major concerns restraining the growth of the market. The complex nature of neurological disorders often necessitates sophisticated and specialized therapeutic interventions, leading to elevated research and development expenses. Additionally, the stringent regulatory requirements imposed by health authorities contribute to the lengthy and resource-intensive process of bringing CNS drugs to market. These substantial costs are then transferred to end-users, comprising patients and healthcare systems, thereby limiting accessibility and affordability of the CNS drugs. Thus, the high cost of the central nervous system (CNS) therapeutic drug might restrain the growth of the market.

The central nervous system (CNS) therapeutics market is segmented based on disease type and region. By disease type, it is divided into neurovascular diseases, CNS trauma, mental health, neurodegenerative diseases, infectious diseases, cancer, and others. The mental health segment is further segmented into mental health anxiety disorders, epilepsy, mood disorders, psychotic disorders, and others.

In addition, the neurodegenerative diseases are further classified into Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's Disease, amyotrophic lateral sclerosis, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The major players profiled in the report are Biogen Inc, Johnson and Johnson, Eli Lilly and Company Inc, Merck and Co. Inc, F. Hoffmann-La Roche AG, Novartis AG, Takeda Pharmaceuticals, Viatris, UCB, and Teva Pharmaceutical Industries Ltd.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the central nervous system (cns) therapeutics market analysis from 2023 to 2033 to identify the prevailing central nervous system (cns) therapeutics market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the central nervous system (cns) therapeutics market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global central nervous system (cns) therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Additional company profiles with specific to client's interest
• Expanded list for Company Profiles
• Historic market data

Key Market Segments

By Disease Type

• Neurodegenerative Diseases
  • Disease Type
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Huntington's Disease
  • Amyotrophic Lateral Sclerosis
  • Others
• Infectious Diseases
• CNS Cancer
• Others
• Neurovascular Diseases
• CNS Trauma
• Mental Health
  • Disease Type
  • Anxiety Disorders
  • Epilepsy
  • Mood Disorders
  • Psychotic Disorders
  • Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Johnson and Johnson
• Eli Lilly and Company.
• Merck & Co Inc
• Novartis AG
• Biogen
• Teva Pharmaceutical Industries Ltd.
• F. Hoffmann-La Roche AG
• Takeda Pharmaceutical Company Ltd.
• Viatris Inc.
• UCB Pharma

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Moderate bargaining power of suppliers
  • 3.3.2. Moderate threat of new entrants
  • 3.3.3. Low threat of substitutes
  • 3.3.4. High intensity of rivalry
  • 3.3.5. Low bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Rise in prevalence of the neurological conditions
    • 3.4.1.2. Rise in awareness and diagnosis of CNS disorders
    • 3.4.1.3. Surge in research and development by key players
  • 3.4.2. Restraints
    • 3.4.2.1. High cost of central nervous system (CNS) therapeutics
  • 3.4.3. Opportunities
    • 3.4.3.1. Technological advancements in drug delivery

CHAPTER 4: CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Neurovascular Diseases
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. CNS Trauma
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Mental Health
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
  • 4.4.4. Mental Health Central Nervous System (CNS) Therapeutics Market by Disease Type
• 4.5. Neurodegenerative Diseases
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country
  • 4.5.4. Neurodegenerative Diseases Central Nervous System (CNS) Therapeutics Market by Disease Type
• 4.6. Infectious Diseases
  • 4.6.1. Key market trends, growth factors and opportunities
  • 4.6.2. Market size and forecast, by region
  • 4.6.3. Market share analysis by country
• 4.7. CNS Cancer
  • 4.7.1. Key market trends, growth factors and opportunities
  • 4.7.2. Market size and forecast, by region
  • 4.7.3. Market share analysis by country
• 4.8. Others
  • 4.8.1. Key market trends, growth factors and opportunities
  • 4.8.2. Market size and forecast, by region
  • 4.8.3. Market share analysis by country

CHAPTER 5: CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY REGION

• 5.1. Overview
  • 5.1.1. Market size and forecast By Region
• 5.2. North America
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by Disease Type
  • 5.2.3. Market size and forecast, by country
    • 5.2.3.1. U.S.
    • 5.2.3.1.1. Market size and forecast, by Disease Type
    • 5.2.3.2. Canada
    • 5.2.3.2.1. Market size and forecast, by Disease Type
    • 5.2.3.3. Mexico
    • 5.2.3.3.1. Market size and forecast, by Disease Type
• 5.3. Europe
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by Disease Type
  • 5.3.3. Market size and forecast, by country
    • 5.3.3.1. Germany
    • 5.3.3.1.1. Market size and forecast, by Disease Type
    • 5.3.3.2. France
    • 5.3.3.2.1. Market size and forecast, by Disease Type
    • 5.3.3.3. UK
    • 5.3.3.3.1. Market size and forecast, by Disease Type
    • 5.3.3.4. Italy
    • 5.3.3.4.1. Market size and forecast, by Disease Type
    • 5.3.3.5. Spain
    • 5.3.3.5.1. Market size and forecast, by Disease Type
    • 5.3.3.6. Rest of Europe
    • 5.3.3.6.1. Market size and forecast, by Disease Type
• 5.4. Asia-Pacific
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by Disease Type
  • 5.4.3. Market size and forecast, by country
    • 5.4.3.1. Japan
    • 5.4.3.1.1. Market size and forecast, by Disease Type
    • 5.4.3.2. China
    • 5.4.3.2.1. Market size and forecast, by Disease Type
    • 5.4.3.3. India
    • 5.4.3.3.1. Market size and forecast, by Disease Type
    • 5.4.3.4. Australia
    • 5.4.3.4.1. Market size and forecast, by Disease Type
    • 5.4.3.5. South Korea
    • 5.4.3.5.1. Market size and forecast, by Disease Type
    • 5.4.3.6. Rest of Asia-Pacific
    • 5.4.3.6.1. Market size and forecast, by Disease Type
• 5.5. LAMEA
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by Disease Type
  • 5.5.3. Market size and forecast, by country
    • 5.5.3.1. Brazil
    • 5.5.3.1.1. Market size and forecast, by Disease Type
    • 5.5.3.2. Saudi Arabia
    • 5.5.3.2.1. Market size and forecast, by Disease Type
    • 5.5.3.3. South Africa
    • 5.5.3.3.1. Market size and forecast, by Disease Type
    • 5.5.3.4. Rest of LAMEA
    • 5.5.3.4.1. Market size and forecast, by Disease Type

CHAPTER 6: COMPETITIVE LANDSCAPE

• 6.1. Introduction
• 6.2. Top winning strategies
• 6.3. Product mapping of top 10 player
• 6.4. Competitive dashboard
• 6.5. Competitive heatmap
• 6.6. Top player positioning, 2023

CHAPTER 7: COMPANY PROFILES

• 7.1. Johnson and Johnson
  • 7.1.1. Company overview
  • 7.1.2. Key executives
  • 7.1.3. Company snapshot
  • 7.1.4. Operating business segments
  • 7.1.5. Product portfolio
  • 7.1.6. Business performance
• 7.2. Eli Lilly and Company.
  • 7.2.1. Company overview
  • 7.2.2. Key executives
  • 7.2.3. Company snapshot
  • 7.2.4. Operating business segments
  • 7.2.5. Product portfolio
  • 7.2.6. Business performance
  • 7.2.7. Key strategic moves and developments
• 7.3. Merck & Co Inc
  • 7.3.1. Company overview
  • 7.3.2. Key executives
  • 7.3.3. Company snapshot
  • 7.3.4. Operating business segments
  • 7.3.5. Product portfolio
  • 7.3.6. Business performance
• 7.4. Novartis AG
  • 7.4.1. Company overview
  • 7.4.2. Key executives
  • 7.4.3. Company snapshot
  • 7.4.4. Operating business segments
  • 7.4.5. Product portfolio
  • 7.4.6. Business performance
  • 7.4.7. Key strategic moves and developments
• 7.5. Teva Pharmaceutical Industries Ltd.
  • 7.5.1. Company overview
  • 7.5.2. Key executives
  • 7.5.3. Company snapshot
  • 7.5.4. Operating business segments
  • 7.5.5. Product portfolio
  • 7.5.6. Business performance
  • 7.5.7. Key strategic moves and developments
• 7.6. F. Hoffmann-La Roche AG
  • 7.6.1. Company overview
  • 7.6.2. Key executives
  • 7.6.3. Company snapshot
  • 7.6.4. Operating business segments
  • 7.6.5. Product portfolio
  • 7.6.6. Business performance
• 7.7. Takeda Pharmaceutical Company Ltd.
  • 7.7.1. Company overview
  • 7.7.2. Key executives
  • 7.7.3. Company snapshot
  • 7.7.4. Operating business segments
  • 7.7.5. Product portfolio
  • 7.7.6. Business performance
• 7.8. Viatris Inc.
  • 7.8.1. Company overview
  • 7.8.2. Key executives
  • 7.8.3. Company snapshot
  • 7.8.4. Operating business segments
  • 7.8.5. Product portfolio
  • 7.8.6. Business performance
• 7.9. UCB Pharma
  • 7.9.1. Company overview
  • 7.9.2. Key executives
  • 7.9.3. Company snapshot
  • 7.9.4. Operating business segments
  • 7.9.5. Product portfolio
  • 7.9.6. Business performance
• 7.10. Biogen
  • 7.10.1. Company overview
  • 7.10.2. Key executives
  • 7.10.3. Company snapshot
  • 7.10.4. Operating business segments
  • 7.10.5. Product portfolio
  • 7.10.6. Business performance
  • 7.10.7. Key strategic moves and developments